Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database-Reference-Cited by-同舟云学术

Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database

Published:2021-02-09 Issue:3 Volume:193 Page:532-541
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Jimenez‐Zepeda Victor H.¹^ORCID,Venner Christopher²,McCurdy Arleigh³,Masih‐Khan Esther⁴⁵^ORCID,Atenafu Eshetu G.⁴,Sebag Michael⁶,Stakiw Julie⁷,Song Kevin⁸,LeBlanc Richard⁹,Reiman Tony¹⁰^ORCID,Louzada Martha¹¹,Kotb Rami¹²,Gul Engin⁴,Reece Donna⁴⁵

Affiliation:

1. University of CalgaryArnie Charbonneau Cancer Institute Calgary AlbertaCanada

2. Cross Cancer Institute University of Alberta Edmonton AlbertaCanada

3. The Ottawa Hospital Ottawa OntarioCanada

4. Canadian Myeloma Research Group Toronto OntarioCanada

5. Department of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto ONCanada

6. Departments of Medicine and Oncology Division of Hematology McGill University Montreal QCCanada

7. Saskatoon Cancer Centre University of Saskatchewan Saskatoon SaskatchewanCanada

8. BC Cancer Vancouver General Hospital British Columbia Canada

9. Maisonneuve‐Rosemont Hospital Research Centre University of Montreal Montreal QuebecCanada

10. Department of Oncology Saint John Regional Hospital Saint John NBCanada

11. London Regional Cancer Center London OntarioCanada

12. Cancer Care Manitoba Winnipeg Manitoba Canada

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17350

Reference23 articles.

1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

2. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

3. Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

4. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

5. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database;eJHaem;2024-04-29

2. More intensive therapy has a better effect for frail parents with multiple myeloma;Blood Advances;2023-10-13

3. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study;Journal of Cancer Research and Clinical Oncology;2023-07-07

4. Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan;PLOS ONE;2023-05-31

5. First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium;Clinical Lymphoma Myeloma and Leukemia;2023-05